Thursday, November 29, 2018

Of possible relevance to multiple sclerosis

Noting the post Long-term Rituxan Treatment Is Effective and Safe in MS, Study Shows , one observes
the text reported by Reuters:

Celltrion Inc’s Truxima on Wednesday became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.



Post a Comment

<< Home